What is the recommended treatment approach for a resistant yeast infection?

Treatment of Resistant Yeast Infections

For resistant yeast infections, treatment depends critically on the specific species and site of infection: use amphotericin B deoxycholate (0.3-0.6 mg/kg daily) or flucytosine (25 mg/kg four times daily) for fluconazole-resistant C. glabrata, amphotericin B for C. krusei, and echinocandins or liposomal amphotericin B (3-5 mg/kg daily) for invasive infections with azole- and echinocandin-resistant strains. 1

Algorithmic Approach by Infection Site

Invasive Candidiasis/Candidemia with Suspected Resistance

For patients with suspected azole- and echinocandin-resistant invasive Candida infections:

• First-line: Liposomal amphotericin B 3-5 mg/kg daily 1
• This applies particularly to C. auris and other emerging resistant pathogens 2
• The 2025 ECMM global guideline emphasizes echinocandins (including the new agent rezafungin) as first-line for most invasive candidiasis, but resistance patterns must guide therapy 2

Urinary Tract Infections

For cystitis:

• Fluconazole-resistant C. glabrata: Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days OR oral flucytosine 25 mg/kg four times daily for 7-10 days 1
• C. krusei: Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days 1
• Remove indwelling bladder catheter whenever feasible 1
• Consider amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) for fluconazole-resistant species 1

For pyelonephritis:

• Fluconazole-resistant C. glabrata: Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days with or without oral flucytosine 25 mg/kg four times daily 1
• Alternative: Flucytosine monotherapy 25 mg/kg four times daily for 2 weeks (weaker recommendation) 1
• Eliminate urinary tract obstruction; remove or replace nephrostomy tubes/stents if present 1

Oropharyngeal Candidiasis (Fluconazole-Refractory)

For azole-resistant oropharyngeal disease:

• Preferred: Itraconazole solution 200 mg once daily OR posaconazole suspension 400 mg twice daily for 3 days then 400 mg daily, for up to 28 days 1
• Alternatives: Voriconazole 200 mg twice daily OR amphotericin B deoxycholate oral suspension 100 mg/mL four times daily 1
• Severe refractory cases: Intravenous echinocandin (caspofungin 70 mg loading then 50 mg daily; micafungin 100 mg daily; or anidulafungin 200 mg loading then 100 mg daily) OR intravenous amphotericin B deoxycholate 0.3 mg/kg daily 1

CNS Infections

For resistant CNS candidiasis:

• Initial therapy: Liposomal amphotericin B 5 mg/kg daily, with or without oral flucytosine 25 mg/kg four times daily 1
• Add flucytosine as salvage therapy if no response to initial amphotericin B (though adverse effects are frequent) 1
• Remove infected CNS devices (ventriculostomy drains, shunts) whenever possible 1
• Continue therapy until all signs, symptoms, CSF abnormalities, and radiological findings resolve 1

Ocular Infections

For fluconazole/voriconazole-resistant isolates causing endophthalmitis:

• Liposomal amphotericin B 3-5 mg/kg IV daily, with or without oral flucytosine 25 mg/kg four times daily 1
• With macular involvement: Add intravitreal amphotericin B deoxycholate 5-10 μg/0.1 mL sterile water 1
• Duration: At least 4-6 weeks based on repeated ophthalmological examinations 1

Novel Agents for Resistant Infections

The 2025 global guideline highlights emerging therapies that complement the antifungal armamentarium 2:

• Rezafungin: New echinocandin with once-weekly dosing for select patients requiring prolonged IV therapy 3
• Ibrexafungerp: Novel agent for superficial candidiasis 2
• Oteseconazole: For vulvovaginal candidiasis 2

These agents show promise but have limited clinical data for many forms of candidiasis 2. Rezafungin appears effective for candidemia but evidence for deep-seated infections remains limited 3.

Critical Resistance Patterns to Recognize

Species-specific resistance:

• C. glabrata: Intrinsically reduced azole susceptibility; increasing echinocandin resistance, particularly in C. parapsilosis 3
• C. krusei: Intrinsically fluconazole-resistant 1
• C. auris: Often multidrug-resistant 2

Mechanisms driving resistance include efflux pump overexpression, target site mutations, biofilm formation, and genomic plasticity 4. These mechanisms reduce the efficacy of available therapies and necessitate alternative strategies 4.

Essential Stewardship Measures

• Obtain antifungal susceptibility testing in patients previously treated with azoles, those not responding to treatment, and infections caused by non-albicans species 5
• Incorporate antifungal stewardship into healthcare systems to improve guideline adherence 2
• Use multipronged approaches involving screening, isolation, and environmental cleaning for outbreak control 2
• Strengthen surveillance for resistance patterns 4

Common Pitfalls to Avoid

1. Do not use fluconazole empirically for suspected resistant infections—this delays appropriate therapy and worsens outcomes
2. Do not treat asymptomatic candiduria unless the patient is neutropenic, very low-birth-weight infant (<1500g), or undergoing urologic manipulation 1
3. Do not rely on echinocandins for CNS or ocular infections—they have poor penetration into these sites 2
4. Do not forget source control—remove catheters, drain abscesses, and eliminate urinary obstruction 1

The increasing burden of antifungal resistance, particularly with non-albicans Candida species, highlights the urgent need for optimized therapeutic strategies, improved diagnostic tools, and novel antifungals 4. Combination therapies targeting resistance pathways offer promising alternatives but require further clinical validation 4.